
- /
- Supported exchanges
- / MU
- / D4S.MU
Daiichi Sankyo Company Limited (D4S MU) stock market data APIs
Daiichi Sankyo Company Limited Financial Data Overview
There is no Profile data available for D4S.MU.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News

TAK vs. DSNKY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two stocks is...


IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says
(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit. The error also appeared in an earlier version of the story.) (Reuters) - ...

Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail
Survey with 7,750 participants highlights the urgent need for more and improved access to information about breast cancer and metastatic breast cancer across Europe Results emphasise lack of knowledge...

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy Datopotamab d...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.